LENZ Therapeutics (NASDAQ:LENZ) Stock Rating Upgraded by Zacks Research

Key Points

• Zacks Research upgraded LENZ Therapeutics from “strong sell” to “hold,” while analysts remain divided; the stock has an overall “Moderate Buy” rating and an average price target of $28.80.
• LENZ shares rose 2.8% to open at $4.73, near their 12-month low of $4.53 and well below the 12-month high of $50.40.
• The company beat quarterly expectations, reporting a loss of $1.02 per share versus the expected $1.05 loss and revenue of $5.49 million versus $2.38 million, though it continues to post substantial losses and analysts forecast a full-year loss of $4.18 per share.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) was upgraded by research analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a research report issued on Thursday,Zacks.com reports.

Several other equities analysts also recently weighed in on LENZ. Weiss Ratings downgraded LENZ Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday. Piper Sandler lowered their price target on LENZ Therapeutics from $12.00 to $7.00 and set a "neutral" rating for the company in a research report on Wednesday. Citigroup reaffirmed a "buy" rating on shares of LENZ Therapeutics in a research note on Wednesday. Finally, HC Wainwright reiterated a "buy" rating on shares of LENZ Therapeutics in a research report on Tuesday, July 7th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $28.80.

LENZ Therapeutics Trading Up 2.8%

LENZ opened at $4.73 on Thursday. The stock has a 50-day moving average of $5.64 and a 200 day moving average of $9.01. LENZ Therapeutics has a 12 month low of $4.53 and a 12 month high of $50.40. The firm has a market cap of $148.62 million, a P/E ratio of -1.16 and a beta of 0.65.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.05) by $0.03. The business had revenue of $5.49 million for the quarter, compared to the consensus estimate of $2.38 million. LENZ Therapeutics had a negative return on equity of 53.39% and a negative net margin of 586.74%. On average, research analysts forecast that LENZ Therapeutics will post -4.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LENZ Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Quarry LP purchased a new stake in shares of LENZ Therapeutics in the 3rd quarter worth $27,000. State of Wyoming purchased a new position in shares of LENZ Therapeutics during the fourth quarter valued at $30,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of LENZ Therapeutics during the fourth quarter valued at $32,000. Osaic Holdings Inc. raised its holdings in shares of LENZ Therapeutics by 2,146.2% in the second quarter. Osaic Holdings Inc. now owns 1,168 shares of the company's stock valued at $34,000 after acquiring an additional 1,116 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of LENZ Therapeutics by 51.4% in the second quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company's stock valued at $41,000 after acquiring an additional 477 shares in the last quarter. 54.32% of the stock is owned by institutional investors.

Trending Headlines about LENZ Therapeutics

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: LENZ’s VIZZ prescriptions reportedly increased more than 45% month over month in July, while the company outlined telehealth and national television initiatives intended to support broader product adoption. Lenz outlines July telehealth and national TV push as VIZZ scripts rise over 45% month over month
• Positive Sentiment: HC Wainwright maintained its Buy rating and raised its Q3 2026 EPS forecast to a loss of $1.02 from a loss of $1.15. It also improved its FY2026 estimate to a loss of $4.35 from a loss of $4.74, suggesting somewhat better near-term expectations.
• Neutral Sentiment: The company’s Q2 2026 earnings call focused on VIZZ’s launch progress and commercialization efforts, giving investors additional information about early demand and the strategy for expanding the product’s reach. LENZ Therapeutics, Inc. Q2 2026 Earnings Call Summary
• Negative Sentiment: Bank of America downgraded LENZ on concerns that VIZZ’s launch may be slower than expected, a significant issue for a company whose valuation depends on successful commercial execution. Lenz drops as BofA downgrades on a slower VIZZ launch
• Negative Sentiment: HC Wainwright reduced its longer-term EPS forecasts for FY2027 through FY2029 and sharply cut FY2030 EPS to $0.63 from $2.72. Although the firm remains bullish, the revisions imply a slower path to profitability and weigh on the stock’s long-term outlook.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source